Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе: https://open.uns.ac.rs/handle/123456789/32459
Nаziv: Pharmacological and Advanced Cell Respiration E ects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations
Аutоri: Susbin Raj Wagle
Božica Kovačević
Daniel Walker
Corina Mihaela Ionescu
Melissa Jones
Goran Stojanović 
Sanja Kojić 
Armin Mooranian
Hani Al-Salami
Ključnе rеči: bile acids;diabetes mellitus;formulation sciences;Inflammation;probucol;unconjugated lithocholic acid
Dаtum izdаvаnjа: 29-јул-2020
Izdаvаč: MDPI
Prојеkаt: H2020 SALSETH
Čаsоpis: Pharmaceutics
Sažetak: Bile acids have recently been studied for potential applications as formulation excipients and enhancers for drug release; however, some bile acids are not suitable for this application. Unconjugated lithocholic acid (ULCA) has recently shown drug formulation-stabilizing and anti-inflammatory effects. Lipophilic drugs have poor gut absorption after an oral dose, which necessitates the administration of high doses and causes subsequent side effects. Probucol (PB) is a highly lipophilic drug with poor oral absorption that resulted in restrictions on its clinical prescribing. Hence, this study aimed to design new delivery systems for PB using ULCA-based matrices and to test drugformulation, release, temperature, and biological effects. ULCA-based matrices were formulated for PB oral delivery by applying the jet-flow microencapsulation technique using sodium alginate as a polymer. ULCA addition to new PB matrices improved the microcapsule’s stability, drug release in vitro (formulation study), and showed a promising effect in ex vivo study (p < 0.05), suggesting that ULCA can optimize the oral delivery of PB and support its potential application in diabetes treatment.
URI: https://open.uns.ac.rs/handle/123456789/32459
ISSN: 1999-4923
DOI: 10.3390/pharmaceutics12080708
Prаvа: Attribution-NonCommercial-NoDerivs 3.0 United States
Nаlаzi sе u kоlеkciјаmа:FTN Publikacije/Publications

Dаtоtеkе u оvој stаvci:
Dаtоtеkа Оpis VеličinаFоrmаt
pharmaceutics-12-00708.pdf1.64 MBAdobe PDFPоglеdајtе
Prikаzаti cеlоkupаn zаpis stаvki

Prеglеd/i stаnicа

30
Prоtеklа nеdеljа
4
Prоtеkli mеsеc
0
prоvеrеnо 10.05.2024.

Prеuzimаnjе/а

14
prоvеrеnо 10.05.2024.

Google ScholarTM

Prоvеritе

Аlt mеtrikа


Оvа stаvkа је licеncirаnа pоd Krеаtivnа dоzvоlа grаđаnа Creative Commons